Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Apr;27(4):583–588. doi: 10.1128/aac.27.4.583

Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis.

M D Reed, R C Stern, C A O'Brien, T S Yamashita, C M Myers, J L Blumer
PMCID: PMC180100  PMID: 3859245

Abstract

The pharmacokinetics of imipenem, a new carbapenem antibiotic, and cilastatin, a metabolic inhibitor, were evaluated in 17 patients with cystic fibrosis. Imipenem and cilastatin were combined in a ratio of 1:1 in the infusion solution, and patients intravenously received 30, 60, or 90 mg of imipenem per kg of body weight per day, divided into four equal doses. Pharmacokinetic evaluation after the first dose and again under steady-state conditions revealed biodisposition characteristics which were similar and independent of the daily dose administered. Cilastatin concentrations in serum paralleled those of imipenem. A linear relationship between dose and area under the serum concentration-time curve for both compounds was observed, suggesting a first-order pharmacokinetic process. A total of 50 and 78% of the doses of imipenem and cilastatin, respectively, were recovered unchanged in the urine. The renal clearances of imipenem and cilastatin averaged 54 and 88%, respectively, of the serum clearance. These data suggest that an extrarenal mechanism may be involved in the overall elimination of imipenem. No patient experienced any clinical or biochemical abnormalities during drug therapy.

Full text

PDF
583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvidsson A., Alván G., Strandvik B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatr Scand. 1983 Mar;72(2):293–294. doi: 10.1111/j.1651-2227.1983.tb09715.x. [DOI] [PubMed] [Google Scholar]
  2. Bauer L. A., Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci. 1983 Aug;72(8):978–979. doi: 10.1002/jps.2600720843. [DOI] [PubMed] [Google Scholar]
  3. Brown J. E., Del Bene V. E., Collins C. D. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance. Antimicrob Agents Chemother. 1981 Feb;19(2):248–252. doi: 10.1128/aac.19.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Holsclaw D. S. Cystic fibrosis: overview and pulmonary aspects in young adults. Clin Chest Med. 1980 Sep;1(3):407–421. [PubMed] [Google Scholar]
  5. Jusko W. J., Mosovich L. L., Gerbracht L. M., Mattar M. E., Yaffe S. J. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics. 1975 Dec;56(6):1038–1044. [PubMed] [Google Scholar]
  6. Kearns G. L., Hilman B. C., Wilson J. T. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982 Feb;100(2):312–318. doi: 10.1016/s0022-3476(82)80663-x. [DOI] [PubMed] [Google Scholar]
  7. Kercsmar C. M., Stern R. C., Reed M. D., Myers C. M., Murdell D., Blumer J. L. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):289–295. doi: 10.1093/jac/12.suppl_a.289. [DOI] [PubMed] [Google Scholar]
  8. Kesado T., Hashizume T., Asahi Y. Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics. Antimicrob Agents Chemother. 1980 Jun;17(6):912–917. doi: 10.1128/aac.17.6.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kropp H., Sundelof J. G., Hajdu R., Kahan F. M. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982 Jul;22(1):62–70. doi: 10.1128/aac.22.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Livingston W. K., Elliott A. M., Cobbs C. G. In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp. Antimicrob Agents Chemother. 1981 Jan;19(1):114–116. doi: 10.1128/aac.19.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Marks M. I. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr. 1981 Feb;98(2):173–179. doi: 10.1016/s0022-3476(81)80631-2. [DOI] [PubMed] [Google Scholar]
  12. Myers C. M., Blumer J. L. Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1984 Jul;26(1):78–81. doi: 10.1128/aac.26.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Norrby S. R., Alestig K., Björnegård B., Burman L. A., Ferber F., Huber J. L., Jones K. H., Kahan F. M., Kahan J. S., Kropp H. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother. 1983 Feb;23(2):300–307. doi: 10.1128/aac.23.2.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Norrby S. R., Alestig K., Ferber F., Huber J. L., Jones K. H., Kahan F. M., Meisinger M. A., Rogers J. D. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother. 1983 Feb;23(2):293–299. doi: 10.1128/aac.23.2.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. RIchmond M. H. The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species. J Antimicrob Chemother. 1981 Mar;7(3):279–285. doi: 10.1093/jac/7.3.279. [DOI] [PubMed] [Google Scholar]
  16. Reed M. D., Stern R. C., Bertino J. S., Jr, Myers C. M., Yamashita T. S., Blumer J. L. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr. 1984 Feb;104(2):303–307. doi: 10.1016/s0022-3476(84)81019-7. [DOI] [PubMed] [Google Scholar]
  17. Reed M. D., Stern R. C., Yamashita T. S., Ackers I., Myers C. M., Blumer J. L. Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1984 May;25(5):579–581. doi: 10.1128/aac.25.5.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Romagnoli M. F., Fu K. P., Neu H. C. The antibacterial activity of thienamycin against multiresistant bacteria-comparison with beta-lactamase stable compounds. J Antimicrob Chemother. 1980 Sep;6(5):601–606. doi: 10.1093/jac/6.5.601. [DOI] [PubMed] [Google Scholar]
  19. SHWACHMAN H., KULCZYCKI L. L. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958 Jul;96(1):6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]
  20. Tally F. P., Jacobus N. V., Gorbach S. L. In vitro activity of thienamycin. Antimicrob Agents Chemother. 1978 Sep;14(3):436–438. doi: 10.1128/aac.14.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tischhauser G., Kayser F. H. The in vitro activity of N-formimidoyl thienamycin compared with other broad-spectrum cephalosporins and with clindamycin and metronidazole. Infection. 1983 Jul-Aug;11(4):219–226. doi: 10.1007/BF01641202. [DOI] [PubMed] [Google Scholar]
  22. Weaver S. S., Bodey G. P., LeBlanc B. M. Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother. 1979 Apr;15(4):518–521. doi: 10.1128/aac.15.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Witte J. L., Sapico F. L., Canawati H. N. In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin. Antimicrob Agents Chemother. 1982 Nov;22(5):906–908. doi: 10.1128/aac.22.5.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wood R. E., Boat T. F., Doershuk C. F. Cystic fibrosis. Am Rev Respir Dis. 1976 Jun;113(6):833–878. doi: 10.1164/arrd.1976.113.6.833. [DOI] [PubMed] [Google Scholar]
  25. Wood R. E. Cystic fibrosis: diagnosis, treatment, and prognosis. South Med J. 1979 Feb;72(2):189–202. [PubMed] [Google Scholar]
  26. Yaffe S. J., Gerbracht L. M., Mosovich L. L., Mattar M. E., Danish M., Jusko W. J. Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis. 1977 May;135(5):828–831. doi: 10.1093/infdis/135.5.828. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES